KRP564
血管生成素相关蛋白4, Angiopoietin-related protein 4 , Angiopoietin-like protein 4, Hepatic fibrinogen/angiopoietin-related protein, HFARP, [Cleaved into: ANGPTL4 N-terminal chain; ANGPTL4 C-terminal chain], ARP4, HFARP, PGAR, PP1158, PSEC0166
| Catalog Number | KRP564 |
| Alias | 血管生成素相关蛋白4, Angiopoietin-related protein 4 , Angiopoietin-like protein 4, Hepatic fibrinogen/angiopoietin-related protein, HFARP, [Cleaved into: ANGPTL4 N-terminal chain; ANGPTL4 C-terminal chain], ARP4, HFARP, PGAR, PP1158, PSEC0166 |
| Size | 20ug, 50ug, 100ug, 200ug, 1mg |
| Product Description | Human ANGPTL4(166-406 aa) |
| Molecular Name | ANGPTL4 |
| Product Introduction | 血管生成素相关蛋白4与血管生成和内皮细胞功能相关，调节血管的发育和修复。。 |
| Molecular Weight | 32-38 kDa |
| Expression System | HEK293F Cells |
| Species | Human |
| Concentration | 联系销售经理获得最新批次的浓度 |
| Purity | ≥95% |
| SDS-PAGE | |
| Purification | Affinity Purification |
| Uniprot ID | Q9BY76 |
| Storage Condition | Store the product under sterile conditions after opening at -80℃ for 12 months. Store the lyophilized powder at -20℃. Avoid repeated freeze-thaw cycles. |
| Formulation | Supplied in PBS |
| Shipping Condition | This product is shipped on ice packs or dry ice. |
| Background | Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed:19270337, PubMed:21398697, PubMed:27929370, PubMed:29899144). May also play a role in regulating glucose homeostasis and insulin sensitivity (Probable). Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage (PubMed:14583458, PubMed:17068295). Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro) (PubMed:17068295). Depending on context, may modulate tumor-related angiogenesis (By similarity). {ECO:0000250|UniProtKB:Q9Z1P8, ECO:0000269|PubMed:14583458, ECO:0000269|PubMed:17068295, ECO:0000269|PubMed:19270337, ECO:0000269|PubMed:21398697, ECO:0000269|PubMed:27929370, ECO:0000269|PubMed:29899144, ECO:0000305|PubMed:29899519}.; [ANGPTL4 N-terminal chain]: Mediates inactivation of the lipoprotein lipase LPL, and thereby plays an important role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed:19270337, PubMed:21398697, PubMed:27929370, PubMed:29899144). Has higher activity in LPL inactivation than the uncleaved protein (PubMed:19270337, PubMed:21398697). {ECO:0000269|PubMed:19270337, ECO:0000269|PubMed:21398697, ECO:0000269|PubMed:27929370, ECO:0000269|PubMed:29899144}. |
| Endotoxin | < 0.1 EU per ug |
| Biological Activity | Immobilized Human ANGPTL4 at 1 μg/mL, 100 μL/well, can bind the Human LILRB2 with an ED50 of 70-350 ng/mL. |
| Product Declaration | 该产品仅供科研使用，不可直接用于人体或注射。 |
销售微信
官方公众号
0
